High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia

42Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

We present retrospectively our experience in the use of high-dose chemotherapy and haematopoietic stem cell support (HSCS) for refractory gestational trophoblastic neoplasia (GTN) in the largest series so far reported. In all, 11 patients have been treated at three Trophoblast Centres between 1993 and 2004. The conditioning regimens comprised either Carbop-EC-T (carboplatin, etoposide, cyclophosphamide, paclitaxel and prednisolone) or CEM (carboplatin, etoposide and melphalan) or ICE (ifosfamide, carboplatin, etoposide). Two patients had complete human chorionic gonadotrophin responses, one for 4 and the other for 12 months. Three patients had partial tumour marker responses for 1-2 months. High-dose chemotherapy and HSCS for GTN is still unproven. Further studies are needed, perhaps in high-risk patients who fail their first salvage treatment. © 2005 Cancer Research.

Cite

CITATION STYLE

APA

El-Helw, L. M., Seckl, M. J., Haynes, R., Evans, L. S., Lorigan, P. C., Long, J., … Hancock, B. W. (2005). High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia. British Journal of Cancer, 93(6), 620–621. https://doi.org/10.1038/sj.bjc.6602771

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free